» Articles » PMID: 38682309

Cutibacterium Acnes-derived Extracellular Vesicles Promote Tumor Growth in Renal Cell Carcinoma

Abstract

Bacterial flora are present in various parts of the human body, including the intestine, and are thought to be involved in the etiology of various diseases such as multiple sclerosis, intestinal diseases, cancer, and uterine diseases. In recent years, the presence of bacterial 16S rRNA genes has been revealed in blood, which was previously thought to be a sterile environment, and characteristic blood microbiomes have been detected in various diseases. However, the mechanism and the origin of the bacterial information are unknown. In this study, we performed 16S rRNA metagenomic analysis of bacterial DNA in serum extracellular vesicles from five healthy donors and seven patients with renal cell carcinoma and detected Cutibacterium acnes DNA as a characteristic bacterial DNA in the serum extracellular vesicles of patients with renal cell carcinoma. In addition, C. acnes DNA was significantly reduced in postoperative serum extracellular vesicles from patients with renal cell carcinoma compared with that in preoperative serum extracellular vesicles from these patients and was also detected in tumor tissue and extracellular vesicles from tumor tissue-associated microbiota, suggesting an association between C. acnes extracellular vesicles and renal cell carcinoma. C. acnes extracellular vesicles were taken up by renal carcinoma cells to enhance their proliferative potential. C. acnes extracellular vesicles also exhibited tumor-promoting activity in a mouse model of renal cancer allografts with enhanced angiogenesis. These results suggest that extracellular vesicles released by C. acnes localized in renal cell carcinoma tissues act in a tumor-promoting manner.

Citing Articles

Microbiota and urinary tumor immunity: Mechanisms, therapeutic implications, and future perspectives.

Li D, Wu R, Yu Q, Tuo Z, Wang J, Yoo K Chin J Cancer Res. 2025; 36(6):596-615.

PMID: 39802902 PMC: 11724181. DOI: 10.21147/j.issn.1000-9604.2024.06.03.


Bacterial information in serum extracellular vesicles reflects the inflammation of adherent perinephric fat.

Uemura T, Kawashima A, Jingushi K, Motooka D, Saito T, Sassi N Cancer Sci. 2024; 116(2):338-349.

PMID: 39566543 PMC: 11786307. DOI: 10.1111/cas.16410.


Dysbiosis in Human Urinary Microbiota May Differentiate Patients with a Bladder Cancer.

Vendrell J, Cabello-Aguilar S, Senal R, Heckendorn E, Henry S, Godreuil S Int J Mol Sci. 2024; 25(18).

PMID: 39337643 PMC: 11432408. DOI: 10.3390/ijms251810159.


Different Prostatic Tissue Microbiomes between High- and Low-Grade Prostate Cancer Pathogenesis.

Kim J, Seo H, Kim S, Rahim M, Jo S, Barman I Int J Mol Sci. 2024; 25(16).

PMID: 39201629 PMC: 11354394. DOI: 10.3390/ijms25168943.


Cutibacterium acnes-derived extracellular vesicles promote tumor growth in renal cell carcinoma.

Jingushi K, Kawashima A, Tanikawa S, Saito T, Yamamoto A, Uemura T Cancer Sci. 2024; 115(8):2578-2587.

PMID: 38682309 PMC: 11309925. DOI: 10.1111/cas.16202.

References
1.
Sebestyen A, Kopper L, Danko T, Timar J . Hypoxia Signaling in Cancer: From Basics to Clinical Practice. Pathol Oncol Res. 2021; 27:1609802. PMC: 8262153. DOI: 10.3389/pore.2021.1609802. View

2.
Trivedi V, Noronha V, Sreekanthreddy P, Desai S, Poojary D, Varghese L . Association of with human thyroid cancer. Front Endocrinol (Lausanne). 2023; 14:1152514. PMC: 10668118. DOI: 10.3389/fendo.2023.1152514. View

3.
Rizzo M, Varnier L, Pezzicoli G, Pirovano M, Cosmai L, Porta C . IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma. Front Oncol. 2022; 12:990568. PMC: 9437355. DOI: 10.3389/fonc.2022.990568. View

4.
Crudele L, Gadaleta R, Cariello M, Moschetta A . Gut microbiota in the pathogenesis and therapeutic approaches of diabetes. EBioMedicine. 2023; 97:104821. PMC: 10570704. DOI: 10.1016/j.ebiom.2023.104821. View

5.
Shi J, Wang K, Xiong Z, Yuan C, Wang C, Cao Q . Impact of inflammation and immunotherapy in renal cell carcinoma. Oncol Lett. 2020; 20(5):272. PMC: 7520756. DOI: 10.3892/ol.2020.12135. View